Cervical Cancer Risk Factors for Biopsy: This Dataset is Obtained from UCI Repository and kindly acknowledged! This file contains a List of Risk Factors for Cervical Cancer leading to a Biopsy Examination! About 11,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades. Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test. AGE Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30. Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papilloma virus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50. SOCIOECONOMIC AND ETHNIC FACTORS Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening. These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services. HIGH SEXUAL ACTIVITY Human papilloma virus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer. Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis).Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection. FAMILY HISTORY Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer. USE OF ORAL CONTRACEPTIVES Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.) The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells. HAVING MANY CHILDREN Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV. SMOKING Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV. IMMUNOSUPPRESSION Women with weak immune systems, (such as those with HIV / AIDS), are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer. DIETHYLSTILBESTROL (DES) From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prsecribed.

Breast cancer remains a significant health concern for women in the United States, with the risk increasing as women age. For women aged 30, the probability of developing invasive breast cancer in the next ten years is *** percent. However, this risk rises substantially to *** percent for women in their ***. The lifetime risk of developing invasive breast cancer for American women stands at **** percent, highlighting the importance of regular screenings and early detection. Prevalence and impact As of January 2022, approximately **** million women in the U.S. had been diagnosed with breast cancer and survived. While breast cancer is the most common type of cancer among women in the country, lung and bronchus cancer accounts for the highest number of cancer-related deaths. Despite this, breast cancer remains a leading cause of concern, with an estimated ******* new cases among women in 2025. The impact of breast cancer extends beyond those diagnosed, as a 2022 survey found that about a quarter of women reported they or a family member had a history of the disease. Trends and developments Encouragingly, breast cancer mortality rates have decreased over recent decades. In 2022, the death rate due to breast cancer was **** per 100,000 population, a significant improvement from **** per 100,000 in 1990. This decline is attributed to factors such as early detection, improved therapies, and increased awareness of risk factors. However, breast cancer remains the second most deadly form of cancer among women in the United States. In 2025, there were estimated to be around 42,170 deaths due to breast cancer among women in the United States.

In 2018, the share of women aged 50-75 years who had received a breast cancer screening in the past two years was lowest in Alaska (67.3 percent) and highest in Rhode Island (87 percent). This statistic displays the percentage of U.S. women aged 50-75 years who received a breast cancer screening in the past two years as of 2018.

Some racial and ethnic categories are suppressed for privacy and to avoid misleading estimates when the relative standard error exceeds 30% or the unweighted sample size is less than 50 respondents.

Data Source: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey (BRFSS) Data

Why This Matters

Breast cancer is the most commonly diagnosed cancer in women and people assigned female at birth (AFAB) and the second leading cause of cancer death in the U.S. Breast cancer screenings can save lives by helping to detect breast cancer in its early stages when treatment is more effective.

While non-Hispanic white women and AFAB individuals are more likely to be diagnosed with breast cancer than their counterparts of other races and ethnicities, non-Hispanic Black women and AFAB individuals die from breast cancer at a significantly higher rate than their counterparts races and ethnicities.

Later-stage diagnoses and prolonged treatment duration partly explain these disparities in mortality rate. Structural barriers to quality health care, insurance, education, affordable housing, and sustainable income that disproportionately affect communities of color also drive racial inequities in breast cancer screenings and mortality.

The District Response

Project Women Into Staying Healthy (WISH) provides free breast and cervical cancer screenings to uninsured or underinsured women and AFAB adults aged 21 to 64. Patient navigation, transportation assistance, and cancer education are also provided.

DC Health’s Cancer and Chronic Disease Prevention Bureau works with healthcare providers to improve the use of preventative health services and provide breast cancer screening services.

DC Health maintains the District of Columbia Cancer Registry (DCCR) to track cancer incidences, examine environmental substances that cause cancer, and identify differences in cancer incidences by age, gender, race, and geographical location.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

https://news.yale.edu/sites/default/files/styles/featured_media/public/ynews-cancer-healthy_137381816.jpg?itok=HN73dW20&c=a75e254fe1da31f2732f6b0d7bce1413" alt="Cancer">

The dataset appears to contain information on the risk of developing or dying from various types of cancer for both males and females.

The columns include:

Gender: The type of cancer or category (e.g., "Any cancer", "Bladder", etc.). Risk of developing (Male): The percentage risk and the equivalent "one in _ person" statistic. Risk of dying (Male): The percentage risk and the equivalent "one in _ person" statistic. Risk of developing (Woman): The percentage risk and the equivalent "one in _ person" statistic. Risk of dying (Woman): The percentage risk and the equivalent "one in _ person" statistic.

Columns in the Dataset Gender Risk of developing (Male): Percentage Risk of developing (Male): One in _ Person Risk of dying (Male): Percentage Risk of dying (Male): One in _ Person Risk of developing (Woman): Percentage Risk of developing (Woman): One in _ Person Risk of dying (Woman): Percentage Risk of dying (Woman): One in _ Person

Introduction Clustered within the nomenclature of Asian American are numerous subgroups, each with their own ethnic heritage, cultural, and linguistic characteristics. An understanding of the prevailing health knowledge, attitudes, and screening behaviors of these subgroups is essential for creating population-specific health promotion programs. Methods Korean American women (123) completed baseline surveys of breast cancer knowledge, attitudes, and screening behaviors as part of an Asian grocery store-based breast cancer education program evaluation. Follow-up telephone surveys, initiated two weeks later, were completed by 93 women. Results Low adherence to the American Cancer Society's breast cancer screening guidelines and insufficient breast cancer knowledge were reported. Participants' receptiveness to the grocery store-based breast cancer education program underscores the importance of finding ways to reach Korean women with breast cancer early detection information and repeated cues for screening. The data also suggest that the Asian grocery store-based cancer education program being tested may have been effective in motivating a proportion of the women to schedule a breast cancer screening between the baseline and follow-up surveys. Conclusion The program offers a viable strategy to reach Korean women that addresses the language, cultural, transportation, and time barriers they face in accessing breast cancer early detection information.

The proportion of women eligible for screening who have had a test with a recorded result at least once in the previous 36 months.RationaleBreast screening supports early detection of cancer and is estimated to save 1,400 lives in England each year. This indicator provides an opportunity to incentivise screening promotion and other local initiatives to increase coverage of breast screening.Improvements in coverage would mean more breast cancers are detected at earlier, more treatable stages.Breast screening supports early detection of cancer and is estimated to save 1,400 lives in England each year. This indicator provides an opportunity to incentivise screening promotion and other local initiatives to increase coverage of breast screening.Improvements in coverage would mean more breast cancers are detected at earlier, more treatable stages.Definition of numeratorTested women (numerator) is the number of eligible women aged 53 to 70 registered with a GP with a screening test result recorded in the past 36 months.Definition of denominatorEligible women (denominator) is the number of women aged 53 to 70 years resident in the area (determined by postcode of residence) who are eligible for breast screening at a given point in time, excluding those whose recall has been ceased for clinical reasons (for example, due to previous bilateral mastectomy).CaveatsData for ICBs are estimated from local authority data. In most cases ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and Wiltshire;Bedfordshire, Luton and Milton Keynes;Buckinghamshire, Oxfordshire and Berkshire West;Cambridgeshire and Peterborough;Frimley;Hampshire and Isle of Wight;Hertfordshire and West Essex;Humber and North Yorkshire;Lancashire and South Cumbria;Norfolk and Waveney;North East and North Cumbria;Suffolk and North East Essex;Surrey Heartlands;Sussex;West Yorkshire.Please be aware that the April 2019 to March 2020, April 2020 to March 2021 and April 2021 to March 2022 data covers the time period affected by the COVID19 pandemic and therefore data for this period should be interpreted with caution.This indicator gives screening coverage by local authority . This is not the same as the indicator based on population registered with primary care organisations which include patients wherever they live. This is likely to result in different England totals depending on selected (registered or resident) population footprint.The indicator excludes women outside the target age range for the screening programme who may self refer for screening.Standards say "Women who are ineligible for screening due to having had a bilateral mastectomy, women who are ceased from the programme based on a ‘best interests’ decision under the Mental Capacity Act 2005 or women who make an informed choice to remove themselves from the screening programme will be removed from the numerator and denominator.There are a number of categories of women in the eligible age range who are not registered with a GP and subsequently not called for screening as they are not on the Breast Screening Select (BS Select) database. Screening units have a responsibility to maximise coverage of eligible women in their target population and should therefore be accessible to women in this category through self referral and GP referral ."This indicator gives screening coverage by local authority . This is not the same as the indicator based on population registered with primary care organisations which include patients wherever they live. This is likely to result in different England totals depending on selected (registered or resident) population footprint.

Background This study sought to describe the pattern of complementary/alternative medicine (CAM) use among a group of patients with advanced breast cancer, to examine the main reasons for their CAM use, to identify patient's information sources and their communication pattern with their physicians. Methods Face-to-face structured interviews of patients with advanced-stage breast cancer at a comprehensive oncology center. Results Seventy three percent of patients used CAM; relaxation/meditative techniques and herbal medicine were the most common. The most commonly cited primary reason for CAM use was to boost the immune system, the second, to treat cancer; however these reasons varied depending on specific CAM therapy. Friends or family members and mass media were common primary information source's about CAM. Conclusions A high proportion of advanced-stage breast cancer patients used CAM. Discussion with doctors was high for ingested products. Mass media was a prominent source of patient information. Credible sources of CAM information for patients and physicians are needed.

A survey of women in the United States from 2025 found that around half would be very likely to get a cervical cancer screening if their provider recommended it. This statistic shows the percentage of women in the United States who would likely get a cervical cancer screening in select circumstances as of 2025.

PurposeCervical cancer screening has been successful in reducing the rates of cervical cancer in developed countries, but this disease remains the leading cause of cancer deaths among women in sub-Saharan Africa. We sought to understand factors associated with limited uptake of screening services in our cervical cancer-screening program in Western Kenya.Participants and MethodsUsing items from a previously validated cancer awareness questionnaire repurposed for use in cervical cancer and culturally adapted for use in Kenya, we interviewed 2,505 women aged 18–55 years receiving care in gynecology clinics or seeking other services in 4 health facilities in Western Kenya between April 2014 and September 2014. We used logistic regression modeling to assess factors associated with uptake (or non-uptake), associated odds ratios (ORs) and the 95% confidence intervals (95% CI).ResultsOnly two hundred and seventy-three women out of 2505 (11%) accepted VIA cervical cancer screening. Knowledge of just how women are screened for cervical cancer was significantly associated with reduced uptake of cervical cancer screening (OR: 0.53; CI 0.38–0.73) as was fear that screening would reveal a cancer (OR 0.70; CI 0.63–0.77), and reliance on prayer with the onset of illness (OR 0.43; CI 0.26–0.71). Participants who thought that one should get cervical cancer screening even if there were no symptoms were more than twice as likely to accept cervical cancer screening (OR 2.21; 95% CI 1.24–3.93). Older patients, patients living with HIV and women who do not know if bleeding immediately after sex might be a sign of cervical cancer were also more likely to accept screening (OR 1.03, CI 1.02–1.04; OR 1.78, CI 1.01–3.14; OR 2.39, CI 1.31–4.39, respectively).ConclusionsIn our population, a high percent of women knew that it is appropriate for all women to get cervical cancer screening, but only a small proportion of women actually got screening. There may be an opportunity to design educational materials for this population that will not only encourage participation in cervical cancer screening but also remediate misconceptions. The discussion illustrates how our findings could be used in such an effort.

The population of Middle Tennessee was assessed using publically available data collected in 2009 describing demographic and breast cancer-related characteristics of the population.*The value for each breast cancer risk factor was determined for each Middle Tennessee County, and counties were then ranked in numerical order from lowest to highest. The numerically ranked counties were then subdivided into quartiles, such that the three counties with the lowest risk factor values were placed in Quartile 1, and those with the highest were placed in Quartile 4. The range of risk factor values encompassed by each quartile are shown.1The percentage of the total female population in the county that is over the age of 50 years (a surrogate for menopause).2The breast cancer incidence per 100,000 women. 3Breast cancer mortality per 100,000 women.4The percentage of all breast cancers that were diagnosed at Stage IV.5The percentage of all breast cancers that were diagnosed without a prior mammographic screening.6The percentage of the female population lacking any form of health insurance.7The median household income.8The percentage of the population possessing higher than a high school level education.9The percentage of the population that is not Caucasian.

Background and aimThis study aims to analyze the worldwide prevalence, mortality rates, and disability-adjusted life years (DALYs) attributed to breast cancer in women between 1990 and 2019. Additionally, it seeks to forecast the future trends of these indicators related to the burden of breast cancer in women from 2020 to 2030.MethodsData from the Global Burden of Disease Study (GBD) 2019 was analyzed to determine the age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) of DALYs due to breast cancer in women across 204 countries and territories from 1990 to 2019. Socio-economic development levels of countries and regions were assessed using Socio-demographic Indexes, and trends in the burden of breast cancer in women worldwide from 2020 to 2030 were projected using generalized additive models (GAMs).ResultsThe estimated annual percentage change (EAPC) in the ASIR breast cancer in women globally was 0.36 from 1990 to 2019 and is expected to increase to 0.44 from 2020 to 2030. In 2019, the ASIR of breast cancer in women worldwide was 45.86 and is projected to reach 48.09 by 2030. The burden of breast cancer in women generally rises with age, with the highest burden expected in the 45–49 age group from 2020 to 2030. The fastest increase in burden is anticipated in Central sub-Saharan Africa (EAPC in the age-standardized death rate: 1.62, EAPC in the age-standardized DALY rate: 1.52), with the Solomon Islands (EAPC in the ASIR: 7.25) and China (EAPC in the ASIR: 2.83) projected to experience significant increases. Furthermore, a strong positive correlation was found between the ASIR breast cancer in women globally in 1990 and the projected rates for 2030 (r = 0.62).ConclusionThe anticipated increase in the ASIR of breast cancer in women globally by 2030 highlights the importance of focusing on women aged 45–49 in Central sub-Saharan Africa, Oceania, the Solomon Islands, and China. Initiatives such as breast cancer information registries, raising awareness of risk factors and incidence, and implementing universal screening programs and diagnostic tests are essential in reducing the burden of breast cancer and its associated morbidity and mortality.

This dataset presents the footprint of participation statistics in the National Cervical Screening Program (NCSP) for women aged 20 to 69, by age group. The NCSP began in 1991. It aims to reduce cervical cancer cases, illness and deaths in Australia. The data spans the years of 2014-2016 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

Cancer is one of the leading causes of illness and death in Australia. Cancer screening programs aim to reduce the impact of selected cancers by facilitating early detection, intervention and treatment. Australia has three cancer screening programs:

• BreastScreen Australia

• National Cervical Screening Program (NCSP)

• National Bowel Cancer Screening Program (NBCSP)

The National cancer screening programs participation data presents the latest cancer screening participation rates and trends for Australia's 3 national cancer screening programs. The data has been sourced from the Australian Institute of Health and Welfare (AIHW) analysis of National Bowel Cancer Screening Program register data, state and territory BreastScreen Australia register data and state and territory cervical screening register data.

For further information about this dataset, visit the data source:Australian Institute of Health and Welfare - National Cancer Screening Programs Participation Data Tables.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• Participation in the NCSP for this report was defined as the percentage of women in the population aged 20-69 who had at least one Pap test in a 2-year period. Participation rates were calculated using the average of the Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females aged 20-69 for the relevant 2-year reporting period adjusted for the estimated proportion of women who have had a hysterectomy.

• A PHN was assigned to women using a postcode to PHN correspondence. Because these are based only on postcode, these data will be less accurate than those published by individual states and territories.

• Postcode is used for mailing purposes and may not reflect where a woman resides.

• Some postcodes (and hence women) cannot be attributed to a PHN and therefore these women were excluded from the analysis. This is most noticeable in the Northern Territory but affects all states and territories to some degree.

• Totals may not sum due to rounding.

• The time period of some PHN data presented is prior to the initiation of PHNs, which were in established in June 2015.

• Some duplication may occur where the same test is reported to the cervical screening register in two or more jurisdictions. This may lead to erroneous results when focusing on smaller geographical areas. This may affect border areas more than others.

• Data are preliminary and subject to change.

• The 2014-2015 period covers 1 January 2014 to 31 December 2015, and the 2015-2016 period covers 1 January 2015 to 31 December 2016.

• PHN205 Murray includes Albury, NSW.

This statistic shows the percentage of women in the U.S. who had a mammogram within the past two years as of 2020-2022, by state. According to the data, **** percent of women in Rhode Island had a mammogram within the past 2 years. Massachusetts and Puerto Rico followed closely with **** percent and ** percent respectively.

IntroductionCervical cancer (CC) is the fourth most common cancer among women. It can be cured if diagnosed at an early stage and treated promptly. The World Health Organization suggests that 70% of women should be screened with a high-performance test by the age of 35. This paper reports a protocol to assess the effect of two modalities of organized CC screening programmes on CC screening uptake.Methods and analysisDesign and setting: The design involves a 3-arm randomized controlled study performed in a French geographic area on the west coast. A total of 1,395 general practitioners will be randomized, depending on their general practice surgeries. Participants: The design is based on a total of 94,393 women aged 40 to 65 years who are eligible for CC screening. Intervention: In the “optimized cancer screening” group, the intervention will combine sending invitation letters to non-adherent women with sending general practitioners (GPs) a list of their non-adherent patients. In the “standard cancer screening” group, the intervention will be limited to sending invitation letters to non-adherent women. In the “usual care” group, no letter will be sent either to women or to their GPs. Primary endpoint: CC screening test uptake will be assessed after a 6-month follow-up period. Statistical analysis: The percentage of women who are up-to-date with their screening at 6 months after the intervention will be compared across arms using a generalized mixed linear model.DiscussionA large-scale randomized trial of this nature is unprecedented. The study will enable us to assess a strategy relying on GPs, identified as the coordinators in this screening strategy. The study results should help policy makers to implement organized CC screening programs in the future.Ethics and disseminationThe study was approved was approved by the Ethics Committee of the National College of Teaching General practitioners (IRB00010804). It was recorded in ClinicalTrials.gov on the number NCT04689178 (28 December 2020). The study findings will be used for publication in peer-reviewed scientific journals and presentations in scientific meetings.

Background: Breast cancer continues to be a public health issue in Botswana. However, there is limited evidence on the association of risk factors with the stages at which diagnosis is done. This study provides evidence on association between risk factors and the stages at which breast cancer is diagnosed among adult females in Botswana.Methods: A cross‐sectional study of 211 Botswana adult women with confirmed breast cancer at public oncology centers was conducted over 10 months in 2022. Data on known risk factors was collected, and statistical tests performed using STATA.Results: The median age of participants at the time of first diagnosis was 50 years. Forty-six percent (46%) of the diagnosed women had advanced stages of breast cancer. Univariate analysis showed significant association of the following four factors with late breast cancer diagnosis; single and never married (OR 0.18, 95% CI: 0.036-0.932), history of iregular menses (OR 1.63, 95% CI: 1.013-2.627), breast cup size (OR 0.57, 0.336-0.968), and age at first full-time pregnancy (OR 0.86, 0.606-1.209). In a bivariate analysis, occupation (p = 0.029), age at first full-term pregnancy (p = 0.042) and type of current breast cancer (p = 0.002) were observed to be associated with late breast cancer diagnosis among women in Botswana. In a multivariate analysis, known second degree family history (OR 0.34, 95% CI: 0.129-0.893) and ductal carcinoma (OR 2.56, 95% CI: 1.083-6.071) were significant predictors of late breast cancer diagnosis among women in four cancer designated catchment centres in Botswana.Conclusion: Women in Botswana present with advanced stages of breast cancer at time of first diagnosis. The risk factors associated with this delayed diagnosis have been identified. We recommend upscaled campaigns targeting women to raise awareness of risk factors and the importance of early detection and access to care.

BackgroundDespite women with criminal justice involvement reporting routine Papanicolaou (Pap) testing, significant disparities in cervical cancer outcomes exist when compared to women without criminal justice involvement. A possible reason for the discrepancy is that this group of women may be misreporting Pap testing. The objective of this study was to validate self-reported cervical cancer screening among women leaving jails.MethodsWe used three methods to validate self-reported cervical cancer screening for women recently released from jail: 1) Medical record review; 2) Semi-structured interview; 3) Pap test knowledge survey. After validating women’s self-reported Pap tests with a review of their medical records, we scored interviews for Pap test recall, and used Pap test knowledge survey scores to compare scores between women who accurately reported Pap tests vs. those who did not.ResultsSixty-one percent (N = 14/23) self-reported cervical cancer screenings were accurate per medical record review. Comparing participants who did and did not accurately self-report a Pap test, we found a significant difference in Pap test recall scores (1.90 vs. 0.00, t = 3.87, p < .01) and Pap test knowledge scores (13.50 vs. 12.13, t = 2.42, p < .05).ConclusionSelf-report of cervical cancer screening was more likely to be accurate if a woman’s Pap test knowledge was high. Clinicians might take extra care in describing screening and distinguishing between Pap tests and pelvic exams to support the cervical health of women with lower knowledge.

IntroductionThe objective of this study is to compare different methods for measuring breast density, both visual assessments and automated volumetric density, in a breast cancer screening setting. These measures could potentially be implemented in future screening programmes, in the context of personalised screening or screening evaluation.Materials and MethodsDigital mammographic exams (N = 992) of women participating in the Dutch breast cancer screening programme (age 50–75y) in 2013 were included. Breast density was measured in three different ways: BI-RADS density (5th edition) and with two commercially available automated software programs (Quantra and Volpara volumetric density). BI-RADS density (ordinal scale) was assessed by three radiologists. Quantra (v1.3) and Volpara (v1.5.0) provide continuous estimates. Different comparison methods were used, including Bland-Altman plots and correlation coefficients (e.g., intraclass correlation coefficient [ICC]).ResultsBased on the BI-RADS classification, 40.8% of the women had ‘heterogeneously or extremely dense’ breasts. The median volumetric percent density was 12.1% (IQR: 9.6–16.5) for Quantra, which was higher than the Volpara estimate (median 6.6%, IQR: 4.4–10.9). The mean difference between Quantra and Volpara was 5.19% (95% CI: 5.04–5.34) (ICC: 0.64). There was a clear increase in volumetric percent dense volume as BI-RADS density increased. The highest accuracy for predicting the presence of BI-RADS c+d (heterogeneously or extremely dense) was observed with a cut-off value of 8.0% for Volpara and 13.8% for Quantra.ConclusionAlthough there was no perfect agreement, there appeared to be a strong association between all three measures. Both volumetric density measures seem to be usable in breast cancer screening programmes, provided that the required data flow can be realized.

The proportion of breast cancer subtypes and confidence/probability intervals among the observed and imputed datasets.